LH
Labcorp Holdings Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.6% ·
share flow +6.1% ·
net new positions -5.9%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 88.13K | $17.42M | n/a | n/a |
| Q2 2026 | 158 | +5 | 56.54M | $15.82B | +9 | −3 |
| Q1 2026 | 155 | +1 | 55.32M | $14.74B | +4 | −4 |
| Q4 2025 | 153 | -1 | 61.82M | $15.50B | +1 | −1 |
| Q3 2025 | 19 | 0 | 33.10M | $9.50B | n/a | −1 |
| Q2 2025 | 17 | -1 | 30.31M | $7.95B | +1 | −2 |
| Q1 2025 | 15 | +2 | 7.94M | $1.85B | +2 | n/a |
| Q4 2024 | 13 | 0 | 9.58M | $2.20B | +2 | −2 |
| Q3 2024 | 12 | +1 | 4.32M | $962.67M | +2 | −1 |
| Q2 2024 | 11 | n/a | 5.93M | $1.21B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 9.88M | n/a | $2.59B | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 9.06M | n/a | $2.38B | 0.0% | n/c | 1 | SEC ↗ ×21 |
| 3 | State Street Global Advisors ✦ (passive) | 3.86M | +0.9% | $1.01B | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.11M | +2.2% | $552.44M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 1.82M | +584.9% | $476.92M | 0.1% | ▲ Add | 5 | SEC ↗ ×8 |
| 6 | Fidelity (FMR) ✦ | 1.67M | n/a | $439.70M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 7 | Norges Bank ✦ (passive) | 1.00M | +1.9% | $263.07M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Marshall Wace ✦ | 348.10K | +402.7% | $91.38M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 156.71K | -4.3% | $40.81M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 10 | Citadel Advisors ✦ | 140.26K | +5976.9% | $36.82M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 11 | T. Rowe Price ✦ | 120.51K | -40.9% | $31.64M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Gotham Asset Management ✦ | 68.28K | +8.7% | $17.92M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 23.70K | -66.2% | $6.22M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 22.37K | New | $5.87M | 0.0% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 16.59K | -75.4% | $4.36M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 2.77K | -84.7% | $727,415 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 1.66K | -9.2% | $435,858 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $5.87M | 0.0% |
Exited
| Point72 Asset Management | $25.55M | was 0.1% |
| D. E. Shaw & Co. | $7.30M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,014 holders, 76.41M shares, $19.36B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.00K sh · $954,060
Officer, Director · 4.67K sh · $1.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology